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Abstract
Background: Down syndrome (DS) is caused by trisomy of all or part of chromosome 21. To further
understanding of DS we are working with a mouse model, the Tc1 mouse, which carries most of human
chromosome 21 in addition to the normal mouse chromosome complement. This mouse is a model for human
DS and recapitulates many of the features of the human syndrome such as specific heart defects, and cerebellar
neuronal loss. The Tc1 mouse is mosaic for the human chromosome such that not all cells in the model carry it.
Thus to help our investigations we aimed to develop a method to identify cells that carry human chromosome 21
in the Tc1 mouse. To this end, we have generated a panel of antibodies raised against proteins encoded by genes
on human chromosome 21 that are known to be expressed in the adult brain of Tc1 mice
Results: We attempted to generate human specific antibodies against proteins encoded by human chromosome
21. We selected proteins that are expressed in the adult brain of Tc1 mice and contain regions of moderate/low
homology with the mouse ortholog. We produced antibodies to seven human chromosome 21 encoded proteins.
Of these, we successfully generated three antibodies that preferentially recognise human compared with mouse
SOD1 and RRP1 proteins on western blots. However, these antibodies did not specifically label cells which carry a
freely segregating copy of Hsa21 in the brains of our Tc1 mouse model of DS.
Conclusions: Although we have successfully isolated new antibodies to SOD1 and RRP1 for use on western blots,
in our hands these antibodies have not been successfully used for immunohistochemistry studies. These antibodies
are freely available to other researchers. Our data high-light the technical difficulty of producing species-specific
antibodies for both western blotting and immunohistochemistry.
Background
Down syndrome (DS) is the most common genetic
cause of intellectual disability and is also associated with
a number of other medical problems including heart
defects, early onset Alzheimer’s disease and leukaemia
[1]. DS is caused by trisomy of human chromosome 21
and is a complex genetic disorder in which the pheno-
type arises from abnormal dosage of otherwise normal
genes.
In order to investigate the relationship between phe-
notype and causative dosage sensitive genes in DS, we
created the Tc1 mouse strain which carries a freely seg-
regating copy of human chromosome 21 (Hsa21) in
addition to a full complement of mouse chromosomes
[2]. There are deletions in this Hsa21 [2] but at least
83% of the human genes are present in three copies
(one human, two endogenous mouse homologs). There-
fore, Tc1 mice are trisomic for the majority of genes on
Hsa21 and several different investigations have shown
they do indeed have phenotypes which are strikingly
similar to those found in individuals with DS [2-5].
However, the Tc1 mouse is mosaic for Hsa21, owing
to stochastic loss of the human chromosome in cells
after fertilisation. Thus the mice have some cells that
contain Hsa21 and some that are euploid, which have
the normal mouse chromosome complement. The
degree of mosaicism differs between tissues and is
reported to vary between individual mice; in one survey
carried out by genomic quantitative-PCR, on 8 animals,
between 7 and 77% of cells in the brain of Tc1 mice
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carried the Hsa21 (mean 53%) [2]. When chromosome
21 content was assessed directly by fluorescence in situ
hybridisation with a human specific probe on metaphase
spreads of Tc1 brain cells, between 36 and 94% of the
cells carried Hsa21 [2]. Between 2-4% of people with DS
also have a mixture of euploid and trisomic cells [6,7].
A low proportion of trisomic cells in these individuals is
associated with a reduced severity and incidence of DS
associated phenotypes [8]. Additionally, people without
DS have also been reported to be mosaic for Hsa21 tri-
somic cells, in particular individuals with Alzheimer’s
disease have been reported to have an elevated number
of Hsa21 trisomic cells within their brains [9-11]. The
phenotypic consequences of these observations have yet
to be fully explored.
A study of Hsa21 mosaicism in the Tc1 mouse model
may provide insight into these issues. In particular,
variability in DS associated phenotypes observed in the
Tc1 mouse model may result in part from variation in
the number of Hsa21-containing cells in specific tissues
and/or cell types. For example, only 73% of Tc1 mice
show heart defects at E14.5, whereas the remaining 27%
of their genetically identical, Hsa21 positive, littermates
do not [2]. This may be due to variable penetrance of
the effects of the dosage-sensitive Hsa21 genes, and/or it
may be due to mosaicism in the hearts of these animals.
In addition, if we could identify Hsa21 positive cells in
vivo this may help us investigate the effects of Hsa21
trisomy at the cellular level. Therefore, in an effort to
determine which cells in Tc1 mice carry Hsa21 and thus
measure levels of mosaicism, we generated antibodies
against proteins encoded by Hsa21 that do not cross
react with mouse homologues. We focussed our study
on proteins expressed in brain as this is our primary
organ of interest.
We successfully generated antibodies that preferen-
tially recognised human but not mouse forms of Hsa21-
encoded proteins as shown by western blotting.
However these antibodies were not compatible with
immunohistochemical methods and therefore could not
be used to identify individual cells that carry Hsa21. We
note that these antibodies are available for other inter-
ested laboratories to use.
Results
Choice of candidate proteins
We aimed to generate novel human-specific antibodies
raised against proteins encoded on Hsa21 to identify
Hsa21 positive cells in our Tc1 mouse model of DS.
Our principal goal was to produce a human-specific
antibody that did not react with mouse proteins and
that was highly expressed in the adult brain as this is
our main organ of interest. We used published data and
online resources (NCBI- Gene Expression Nervous
System Atlas, Affymetrix Symatlas/BioGPS) to identify
candidate genes that were reported to be expressed
widely in the brain (Table 1). To avoid generating anti-
bodies against hypothetical proteins we prioritised tar-
gets for which there was evidence of a functional
protein. Regions of low homology between the human
protein and the mouse homologue where then identified
by performing Clustal W alignments. In the case of one
gene, ADARB1, an exon unique to humans was
identified.
The secondary structure and accessibility of these low
homology regions were modelled using PHD and PROF
programmes that were accessed from the Predict Pro-
tein website http://cubic.bioc.columbia.edu/predictpro-
tein/. Additionally, the regions were checked against
published protein structures to confirm accessibility.
The antigenicity of sequences was also estimated using
the method of Jameson and Wolf which combines indi-
cators of hydropathy, secondary structure and structural
flexibility [12]. Candidate sequences were also checked
for consensus sequences for posttranslational modifica-
tions including signal sequence cleavage, glycosylation,
phosphorylation, and myristoylation using algorithms
available from the Predict Protein website [13,14].
Candidate regions that were predicted to be accessible,
not post-translationally modified, and exhibited a mod-
erate/high antigenicity index, were checked for similarity
with mouse proteins using blastp http://blast.ncbi.nlm.
nih.gov/Blast.cgi. Those that were highly similar to
mouse proteins were discarded as candidates. Ten can-
didate polypeptide sequences in eight candidate proteins
were identified: an RNA editase (ADARB1), a Golgi-resi-
dent galactosyltransferase (B3GAL-T5) (two sequences),
a potential neurodevelopmental protein (DOPEY2), the
Golgi enzyme formimidoyltransferase-cyclodeaminase
(FTCD), an RNA processing enzyme (RRP1) (two
sequences), superoxide dismutase 1 (SOD1), a cation
membrane channel (TRPM2) and a histone deubiquiti-
nase (USP16).
Expression of ADARB1, B3GAL-T5, DOPEY2, FTCD,
RRP1, TRPM2 and USP16 was investigated by RT-PCR.
Total RNA was isolated from adult Tc1 mouse brain
and non-transchromosomic littermate control brain, and
subjected to RT-PCR (n = 5). Significant expression of
FTCD could not be detected in human or Tc1 brain
(Figure 1D). Therefore the two identified FTCD poly-
peptide sequences were discarded as potential candi-
dates against which to raise an antibody. The expression
of the other genes of interest was confirmed in the Tc1
brain (Figure 1). Elevated expression of SOD1 in the
Tc1 brain had been previously demonstrated by western
blot [2].
Production, conjugation of the selected peptides to
Keyhole limpet haemocyanin (KHL) and injection of the
Wiseman et al. Journal of Negative Results in BioMedicine 2010, 9:7
http://www.jnrbm.com/content/9/1/7
Page 2 of 12
Table 1 List of Hsa21 genes present in the Tc1 mouse that are expressed in adult brain
Hsa21
encoded
Protein
Evidence of expression in brain Candidate regions and/or reasons for discontinuation
HSPA13/
STCH
Ubiquitous expressed [17] No human specific region
NRIP1 Expressed in mouse brain [18] and Gensat images 24262 and 24263) No human specific region
USP25 Basal expression in all human tissues but high expression only in fetal
brain and adult testis [19,20]
N/A
NCAM2 Expression in adult human brain [21] No human specific region
MRPL39 Expressed in adult mouse and human brain [18,21] Possible region (aa 1-42
MEALAMGSRALRLWLVAPGGGIKWRFIATSSASQLSPTELTE) is
putative mitochondrial targeting sequence [13]
JAM2 Expression in brain restricted to vascular endothelial cells [22,23] N/A
GABPA Expression in adult mouse brain [18] No human specific region
ADAMTS5 Expression in adult mouse brain restricted to Schwann cells [24] N/A
ADAMTS1 Expression in adult rat brain restricted to neuron subpopulation [25] N/A
USP16 Expressed in human and mouse brain [18,21] 1 region used for antibody generation (see table 2).
CCT8/
CCTQ
Expressed in mouse brain [18,26,27] No human specific region
BACH1 Expressed in adult mouse and human brain [21,28] Possible region (aa 676-716
RPPAVLPPCARGNSEPGYARGQESQQMSTATSEQAGPAEQCR)
contains a putative disulphide bond
GRIK1 Expressed in adult mouse and human brain [29,30] No human specific region
TIAM1 Expression in adult mouse and human brain [18] No human specific region
SOD1 Expressed in human and mouse brain
[31,32]
1 region used for antibody generation (see table 2)
CBR1 Expressed in human adult and fetal brain [21,33] No human specific region
CBR3 Expressed in human adult brain [34] Possible region (aa 236-242 GKDSI) similarity with mouse Hy-3
and DNA isomerase 1
DOPEY2/
C21orf5
Expression in cortex, cerebellum, and hippocampus in adult,
widespread expression in embryonic and fetal brain [35-38]
1 region used for antibody generation (see table 2),
2nd region (aa. 671-684 LAANDSERKNSWEP) contains N-
glycosylation site
MORC3 Expressed in adult human brain [21] Possible region cross (aa 665-696
DAVILPSCVEAEAKIHETQETTDKSADDAGC) similar to mouse
Btnl2 and KIF21B
SIM2 Long isoform expressed in adult mouse brain particularly expressed in
amygdala, hippocampus and thalamus, expression in embryonic and
fetal brain, short isoform not expressed in adult brain [39-41]
Possible region (long form aa 613-624 GAAPAASGLAC)
predicted low antigenicity
DSCR3/
DCRA
Expressed in human and mouse adult brain [21,42] No human specific region
DYRK1A Expression in adult mouse and human brain [43-45] No human specific region
KCNJ6/
GIRK2
Expressed in subset of cells throughout mouse brain [46-48] N/A
ETS2 Expressed in human and mouse brain [18,49] No human specific region
PSMG1/
DSCR2
Expressed in adult mouse brain [18,50] No human specific region
B3GALT5 Expressed in adult human and mouse brain [18,51] 1 region used for antibody generation (see table 2)
PCP4/PEP-
19
Expressed restricted to cerebellum and olfactory bulb in adult mouse
and caudate-putamen in human [52-54]
No human specific region
DSCAM Expressed in adult mouse and human brain [55,56] No human specific region
BACE2 Expressed in adult mouse and human brain but at low levels
[18,57-60]
Human specific region of 396 aa isoform (aa380-396
LQCLKFPGLSQQRM) predicted low antigenicity
UMODL1 Expression in embryonic mouse brain restricted to olfactory and
vomeronasal neurons [61]
N/A
ABCG1 Expressed in adult human and mouse brain [21,62,63] No human specific region
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KHL-peptides into New Zealand Rabbits was underta-
ken (21st Century Biochemicals). In the case of B3GAL-
T5 and RRP1 a mixture of two peptides were injected
into each rabbit (Table 2). Sera isolated from the rabbits
after the fifth, sixth and seventh KHL-peptide boost was
affinity purified against the peptide. Sera from the rab-
bits challenged with B3GAL-T5 and RRP1 peptides were
affinity purified against both peptides separately.
Antibodies that recognise a Tc1 Hsa21 specific protein
RRP1
One of the anti-RRP1 antibodies (9644-B), which was
purified against peptide B, recognised a 50 kDa band on
western blots of Tc1 total brain proteins; consistent
with the predicted molecular weight of RRP1 (Figure
2A). A similar band was not observed in non-transchro-
mosomic control mice, indicating that this antibody may
specifically react with human RRP1. RRP1 peptide
sequence B is unique to the human protein and is not
found in mouse RRP1. In addition to the Tc1 specific
band a number of weaker additional bands were
observed in samples of Tc1 and non-Tc1 total brain
proteins. These are likely to represent non-specific inter-
action of the polyclonal antibody with other brain pro-
teins. Despite the relative specificity of the 9644-B
antibody on western blot, a similar pattern and intensity
of staining was observed on Tc1 and non-transchromo-
somic control mouse whole brain sections; intracellular
staining was observed through-out the brain in both
Tc1 and control non-transchromosomic mice (Figure
3A and 3B). Therefore, although 9644-B may be a suita-
ble antibody for western blot studies of RRP1, it cannot
be used to identify Hsa21 positive cells in the brains of
Tc1 mice.
Affinity purified antibody raised against RRP1 peptide
B purified from the second rabbit (9643-B) did not
recognise a Tc1 specific band (Figure 2B). A 50 kDa
protein was weakly detected using this antibody in sam-
ples of Tc1 and control mouse brain; however, peptide
B does not share any homology with mouse RRP1
Table 1 List of Hsa21 genes present in the Tc1 mouse that are expressed in adult brain (Continued)
WDR4 Basal expression in adult tissues only high expression in fetal tissues
[64]
N/A
PKNOX1/
PREP1
Expressed in adult human and mouse brain [65,66] No human specific region
CBS Expressed in astrocytes and Bergmann glial cells only in adult mouse
brain [67]
N/A
U2AF1 Expressed in adult mouse and human brain [21,68] No human specific region
CSTB Expressed in adult mouse and human brain (astrocytes and neurons)
[18,21,69]
No human specific region
NNP1/RRPIB Ubiquitously expressed in all human tissues [21,70] 2 regions used for antibody generation (see table 2)
AGPAT3 Expressed in adult mouse brain [71] No human specific region
TRAPPC1/
TMEM1
Expressed in adult human brain [21] No human specific region
PWP2/
PWP2H
Ubiquitously expressed in human adult tissue [72] No human specific region
PFKL Expressed in adult brain [21,73] No human specific region
TRPM2 Expressed in human and mouse brain also in microglia cell lines and
cultured neurons [74-77]
1 region used for antibody generation (see table 2)
PTTG1IP Expressed in human brain [21,78] 1 possible region (aa 1-29
MAPGVARGPTPYWRLRLGGAALLLLLIPV) putative signal
sequence [14]
ADARB1/
RED1
Expressed in adult mouse and human brain [79-82] 1 region used for antibody generation (see table 2)
FTCD Expressed in fetal human brain and in numerous mammalian cells
types [83,84]
2 possible human specific regions (long isoform aa 423-446
GGPTGGSEAGSLCAADAGGDGGLA and aa 465-495
PPGGQSPGDGRVWRIFQRAHQPEGHHRRGI)
LSS Expressed in adult mouse brain [18] No human specific region
S100Beta Expression in adult mouse and human brain (particularly astrocytes
and spinal, medullar, pontine and deep cerebellar neurons) [18,21,85]
No human specific region
PRMT2 Expressed in human adult brain [21,86] No human specific region
Evidence for expression in adult brain is listed in column two, including evidence for restriction of expression to a subset of cells. In column three candidate
regions with moderate or low homology with their mouse ortholog are identified and any rational for not using the region to attempt to generate an antibody is
described.
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therefore the 50 kDa band detected after probing with
this antibody is highly unlikely to be RRP1.
An antibody affinity purified against RRP1 peptide A
(9644-A) did recognise a band consistent with the mole-
cular weight of RRP1 in samples of both Tc1 and con-
trol brain (Figure 2C). Five of the nineteen amino acids
of peptide A are homologous with the mouse RRP1 pro-
tein sequence including a sequence (K*PA) with high
predicted antigenicity. Therefore the antibody purified
against peptide A may recognise both mouse and
human RRP1 and therefore is not useful to identify
Hsa21 positive cells in the Tc1 model. An antibody affi-
nity purified against peptide A from the other rabbit
(9643-B) did not consistently recognise a band corre-
sponding to the molecular weight of RRP1 (Figure 2D).
This suggests that RRP1 peptide A is not a reliable anti-
gen for the production of rabbit polyclonal antibodies.
Antibodies that did not recognise a Tc1 unique product
SOD1
Immunisation with a single SOD1 peptide generated
anti-SOD1 antibodies (9638 and 9637) that recognised a
Tc1 specific band on western blots of total brain protein
(Figure 2E and 2F). The size of the bands recognised is
consistent with the known molecular weight of the
SOD1 monomer (16 kDa). These antibodies also
detected a band of a comparable molecular weight in
samples of total brain proteins isolated from transgenic
mice that over-express wild-type or mutant (SOD1G93A)
human SOD1 and in samples of recombinant human
SOD1 (wild-type or SOD1G93A) (gift of Ruth Chia) (Fig-
ure 2E and 2F). The 16 kDa band was not observed in
samples of brain from non-transchromosomic control
mice. However, after long exposures a weak band that
was smaller than the predominant 16 kDa band was
detected by both 9637 and 9638 in Tc1 and control
mouse brain samples. This smaller band may be mouse
SOD1; thus antibody 9637 and 9638 may weakly cross-
react with mouse SOD1. Moreover, these antibodies
generated an intracellular staining pattern of similar
intensity on Tc1 and non-transchromosomic control
mice brain sections, which were either paraffin-
embedded or cryopreserved (Figure 3C-F, data not
shown). The antibody does not recognise cells specifi-
cally in the Tc1 brain and therefore cannot be used to
identify these Hsa21 positive cells in our mouse model
for future studies. This result may occur because the
polyclonal antibodies generated recognise non-SOD1
proteins and weakly cross-react with mouse SOD1 in
both Tc1 and control brain, or that the antibodies
Figure 1 Expression of candidate Hsa21 genes in the Tc1 adult
brain. To determine if the candidate genes were expressed, RT-PCR
was undertaken using primers against (B) USP16 (129 base pair
product), (C) B3GAL-T5 (138 base pair product), (D) DOPEY2 (192
base pair product), (E) FTCD (207 base pair product), (F) ADARB1-
primer set 1 (134 or 254 base pair product), (G) RRP1 (173 base pair
product) (H) TRPM2 (181 base pair product) and (I) ADARB1- primer
set 2 (156 base pair product) was undertaken. Primers against (A)
human and mouse DYRK1A (235 base pair product) and (J) mouse
Dyrk1a (793 base pair product) were used as controls. RNA from Tc1
adult mouse brains (Tc1), non-transchromosomic littermate control
adult brains (C), human adult brain (HB) and human adult liver (HL)
was used as indicated.
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Table 2 List of Hsa21 Genes and peptides used to immunise rabbits.
Candidate Protein Molecular
weight of
protein (kDa)
Peptide used to immunise rabbits
(protein accession numbers)
Mean
antigenicity
index
(Jameson
and Wolf)
Double-stranded RNA-specific editase
1 (ADARB1)
80 Acetyl-CNHGSLQPRPPGLLSDPS-amide (ENSP00000374512, amino acid 478-
495)
1.088889
B-1,3-galactosyltransferase 5 (B3GAL-
T5)
36 A. Acetyl-KERMVKGKQLKTFC-amide (ENSP00000343318, ENSP00000369994,
ENSP00000369992, ENSP00000381699, ENSP00000403209 amino acid 82-
93)
0.720833
B.Acetyl-CAAETKEVDQESQRHGDI-amide (ENSP00000343318,
ENSP00000369994, ENSP00000369992, ENSP00000381699,
ENSP00000403209, amino acid 103-119)
1.547647
Protein Dopey 2 (DOPEY2) 258 Acetyl-CFRPVKQRYSVRNSVS-amide (ENSP00000382104, amino acid 455-
470)
1.244375
Ribosomal RNA processing protein 1
homolog A (RRP1)
53 A. Acetyl-GDALSQKRSEKPPAGSIC-amide (ENSP00000291569, amino acid
257-275)
1.745
B. Acetyl-CGARQRRRTPRPLTSARAKA-amide (ENSP00000291569, amino acid
428-446)
1.839474
Transient receptor potential cation
channel subfamily M member 2
(TRPM2)
165, 177 Acetyl-CSWRLQ[Abu]PFGNNDKQESL-amide (ENSP00000381023,
ENSP00000300481, ENSP00000300482, ENSP00000393982,
ENSP00000381026, amino acid 43-59)
1.105882
Superoxide dismutase 1 (SOD1) 16 Acetyl-FEQKESNGPVKVWGSIC-amide (ENSP00000270142, amino acid 21-36,
ENSP00000374645, amino acid 6-17)
0.9875
Ubiquitin carboxyl-terminal hydrolase
16 (USP16)
94 CSTEEVDMKNINMDNDLEV-amide (ENSP00000382857, ENSP00000382858,
ENSP00000334808, amino acid 530-548)
0.930556
Added conjugating cysteine are highlighted in bold, amino acids that are only found in human sequence are underlined. Abu, abbreviation for amino-n-butyric
acid, used to substitute for an internal cysteine residue.
Figure 2 Western blot of total brain proteins probed with affinity purified rabbit polyclonal antibodies. Total brain proteins from Tc1
adult mice (Tc1+), non-transchromosomic littermate control mice (C), transgenic mice that express wild type human SOD1 (Tg(SOD1)2Gur),
transgenic mice that express mutant human SOD1 (Tg(SOD1*G93A)1Gur)and non-transgenic littermate control mice (control), recombinant
human SOD1 wild-type (rSOD1) and human SOD1 G93A (rSOD1*G93A) mutant protein and human recombinant B3GALT5 (amino acids 29-128)
conjugated to GST were used as indicated. To compensate for the high expression level of the human SOD1 transgene in the Tg(SOD1)2Gur
and Tg(SOD1*G93A)1Gur mice a lower amount of total brain proteins were loaded per lane as indicated. Western blots were probed with affinity
purified anti-bodies raised against (A) RRP1 peptide B (9644-B), (B) RRP1 peptide B (9643-B), (C) RRP1 peptide A (9644-A), (D) RRP1 peptide A
(9643-B), (E) SOD1 peptide (9638), (F) SOD1 peptide (9637), (G) ADARB1 peptide (9528), (H) B3Gal-T5 peptide A (9598-A) and (I) B3Gal-T5 peptide
B (9598-B). Closed arrows indicate band of interest, (A-I), open arrows indicate potential mouse SOD1 band (E and F) and 36 kDa band in
PNGase treated samples (H).
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generated only recognise denatured human SOD1. We
have previously tested whether a number of commer-
cially available anti-SOD1 antibodies specifically label
cells in Tc1 brain sections and found that these antibo-
dies were not specific (data not shown).
ADARB1
An affinity purified antibody (9528) that reacted weakly
with a band consistent with the known molecular weight
of the protein, 80 kDa, was isolated from one rabbit
injected with the ADARB1 peptide (Figure 2G). How-
ever, this band was observed in samples of total brain
proteins from both Tc1 and non-transchromosomic
control mice. As ADARB1 peptide sequence used to
challenge the rabbits was unique to human ADARB1
and not found in mouse, the protein recognised by this
antibody is unlikely to be ADARB1. No signal consistent
with the molecular weight of ADARB1 was observed
when western blots of total brain proteins were probed
with affinity purified antibody generated from the sec-
ond rabbit (9529), which was challenged with ADARB1
peptide (data not shown).
B3GALT5
Affinity purified antibodies raised against B3GAL-T5
peptides were used to probe western blots of total brain
proteins from Tc1 and control mice and recombinant
glutathione-S-transferase (GST) tagged human B3GAL-
T5 (amino acids 29-128, Abnova). Recombinant human
B3GAL-T5 was detected using both antibodies (Figure
2H and 2I). A predominant band of 64 kDa and weaker
bands of around 50 kDa were detected in western blots
of Tc1 and control samples probed with antibodies affi-
nity purified against peptide A (9598-A) (Figure 2H). A
Figure 3 Affinity purified anti-RRP1 and SOD1 antibodies do not specifically label cells in the Tc1 mouse model. A similar pattern and
intensity of staining is observed in adult Tc1 (A, C, E) and non-transchromosomic littermate control (B, D, F) cortical brain sections stained with
affinity purified rabbit polyclonal antibodies generated against (A and B) RRP1 peptide B (9644-B), (C and D) SOD1 peptide (9638) and (E and F)
SOD1 peptide (9637). Paraffin embedded sections were pretreated with protease prior to incubation with rabbit polyclonal antibodies, nuclei
were counter-stained with haematoxylin. Scale bar = 50 μm.
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predominant band of 50 kDa and weaker bands of 64,
36 and approximately 28 kDa were detected in western
blots of samples of total brain proteins from Tc1 and
control mice that were probed with antibodies affinity
purified against peptide B (9598-B) (Figure 2I). The
molecular weight of human B3GAL-T5 is 36 kDa. How-
ever, B3GAL-T5 contains three N-glycosylation
sequences (amino acids 130, 174 and 231) that may be
occupied in vivo. Indeed in COS-7 cells a variety of
B3GAL-T5 glycoforms of between 37-50 kDa are
detected by western blot [15]. To investigate if the pro-
tein bands detected in samples of Tc1 and control brain
are glycosylated forms of B3GAL-T5 samples of Tc1
and control brain proteins were treated with PNGase F,
an enzyme that cleaves protein-attached N-linked gly-
cans, before western blotting. De-glycosylation of endo-
genous proteins was confirmed by checking that the
glycoprotein PrP exhibited the expected size shift after
PNGase F treatment (data not shown). Enrichment of a
36 kDa protein was observed in Tc1 and control brain
samples after treatment PNGase F on western blots
probed with the antibody affinity purified against pep-
tide A (9598-A), consistent with this antibody recognis-
ing endogenous B3GAL-T5 (Figure 2H). No enrichment
in a 36 kDa band was observed in the brain samples
treated with PNGase F that were probed with the anti-
body affinity purified against peptide B (9598-B) (Figure
2I). This result suggests that the 50 kDa protein recog-
nised by antibody 9598-B is not a glycosylated form of
B3GAL-T5.
DOPEY2, TRPM2 and USP16
Affinity purified rabbit polyclonal antibodies raised
against DOPEY2 and TRPM2 and USP16 peptides did
not react with a band of the predicted molecular weight,
in western blots of Tc1 and non-transchromosomic con-
trol total brain proteins (data not shown). In addition
the pattern and intensity of staining observed in Tc1
and non-transchromosomic control paraffin-embedded
or cryopreserved brain sections was similar, indicating
that that these antibodies do not recognise a Hsa21 spe-
cific product (data not shown).
Discussion
In order to specifically detect cells carrying Hsa21 in our
Tc1 mice, we carried out extensive literature searches of
both commercial and basic research resources and were
unable to find suitable antibodies that could be used on
fixed tissues and primary cell cultures. Many antibodies
to Hsa21 derived proteins exist, but none that we could
find specifically recognised Hsa21 positive cells in Tc1
mouse brain sections and not control non-transchromo-
somic mouse sections. Therefore we attempted to gen-
erate Hsa21 antibodies that we could use to identify
Hsa21 carrying cells in our model.
From bioinformatics analysis, we identified eight genes
which were present in the Tc1 mouse and which might
make suitable candidates for further analysis. One of
these, FTCD, was not expressed in brain and so we gen-
erated eighteen different antibodies raised against
amino-acid sequences identified from the remaining
seven genes, selecting only sequences which were diver-
gent between mouse and human, and likely to be mod-
erately/highly antigenic.
We generated a panel of antibodies, of which one
antibody (9644-B) raised against RRP1 appeared to be
human specific on western blots, although proved unsui-
table for immunohistochemistry and two new antibodies
raised against SOD1 (9638 and 9637) that appear to pre-
ferentially recognise human SOD1 on western blots, but
do not recognise Hsa21 positive cells in Tc1 brains by
immunohistochemistry.
Conclusion
Having surveyed 295 genes on Hsa21 we are left with
three antibodies that we can use for western blot analy-
sis that will preferentially bind to human protein, and
none that will work by immunohistochemistry. This
illustrates the difficulty of making antibodies that only
recognise a specific human protein but not its mouse
homologue, even with extensive knowledge of the genes
available, their likely antigenicity and the degree of con-
servation between mouse and human. We will now go
on to other methods for detecting Hsa21 in tissue sec-
tions and cultured cells, and we note that the antibodies
we have generated are available to interested
laboratories.
Methods
Animal Welfare
Mice were housed in controlled conditions in accor-
dance with guidance issued by the Medical Research
Council in Responsibility in the Use of Animals for Med-
ical Research (1993) and all experiments were carried
out under License from the UK Home Office.
DNA extraction and Genotyping
DNA was extracted from tail tip (approximately 3mm)
from all samples analysed. Tail tip is lysed overnight using
Proteinase K digestion in nuclei lysis buffer (Promega),
plus 0.12 M EDTA at 55°C. Proteins are precipitated from
the resultant lysate by addition of protein precipitation
solution (Promega), DNA is then precipitated with isopro-
panol and resuspended in DNase free water. Tc1 mice
were genotyped using PCR (Tc1 specific primers f: 5′-
GGTTTGAGGGAACACAAAGCTTAACTCCCA-3′ r: 5′-
ACAGAGCTACAGCCTCTGACACTATGAACT-3′,
control primers f: 5′-TTACGTCCATCGTGGACAGCAT-
3′ r: 5′-TGGGCTGGGTGTTAGTCTTAT-3′). Tc1 mice
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were taken from a colony maintained by mating Tc1
females to F1(129S8 × C57BL/6) males. Both SOD1 trans-
genics were taken from colonies maintained by crossing
male transgenics to female C57BL6/J (Jackson Labora-
tories, Bar Harbour). SOD1 transgenic mice (Tg(SOD1)
2Gur, Jackson and Tg(SOD1*G93A)1Gur; Jackson Labora-
tories, Bar Harbour) were genotyped by PCR (SOD1 speci-
fic primers f: 5′-CATCAGCCC TAATCCATCTGA-3′ r:
5′-CGCGACTAACAATCAAAGTGA-3′, control primers
f: 5′-CTAGGCCACAGAATTGAAAGATCT-3′ r: 5′-
GTAGGTGGAAATTCTAGCATCATC-3′).
RNA extraction and RT-PCR
RNA was extracted from whole brains from 6-10 week old Tc1
and age and sex matched non-transchromosomic controls.
Total RNA was extracted using TRIzol reagent (Invitrogen),
precipitated as per manufactures instructions and resuspended
in DNase-free water. Amounts of RNA were equalised and
cDNA was generated using a standard reverse-transcription
protocol using random primers (Promega), Superscript II (Invi-
trogen), First Strand Buffer (Invitrogen) and dNTPs (Promega).
PCR using primers which amplify a PCR product from both
mouse Dyrk1A and human DYKR1A (f: 5′-GGAGAGACTT-
CAGCATGCAAAC-3′ r: 5′-GCTGGGTCACGGAAGGT
TTG-3′) or mouse DYRK1A (f: 5′-CAAGAAAACAGCTGAT-
GAAGG-3′ r: 5′-AGCCCCTTGTCTCATCGC-3′) were used
to check cDNA. PCR using primers designed to raised a pro-
duct against human but not mouse FTCD (f: 5′-
GAATGCGTCCCCAACTTTTCG-3′ r: 5′-GTCGA-
TAAGTCGGGAAGCTAC-3′), USP16 (f: 5′-AAGCCTT-
CAGTTTGGCTG-3′ r: 5′-GTCCAAACTAAGAACCAGAC-
3′), DOPEY2 (f: 5′-ACCTGAGGTACTCCTTGTTG-3′ r: 5′-
CCAGGAGAGGAAATAACCCG-3′), TRPM2 (f: 5′-GTTC
GTGGATTCCTGAAAAC-3′ r: 5′-TCCAAGTGCTGCT-
CATGC-3′ and f: 5′-TGGCCGTCAGCGTCCACTTC-3′ r: 5′-
TAGTGAGCCCCGAACTCAGC-3′), B3GAL-T5 (f:
5′-CACTGTGGCTTTAGCTTTCAAAC-3′ r: 5′-GGATTTA-
GACTGTACATGC-3′), ADARB1 (f: 5′-TTTAGGCTGAAG-
GAGAATGTC-3′ r: 5′-CCTCTTGCTTTACGATTTGGG-3′
and f: 5′-GTCTCGCTCTTACACCCAG-3′ r: 5′-CCTC
TTGCTTTACGATTTGGG-3′) and RRP1 (f: 5′-TCCCTGAA-
GATGAGATCCCAG-3′ r: 5′-TACACCCCTCCTCCTGCTC-
3′) were used to check the expression of these genes from
Hsa21.
Western blotting
Whole brain from Tc1, Tg(SOD1)2Gur, Tg
(SOD1*G93A)1Gur and aged and sex matched control
non-transgenic mice was homogenized in 9 volumes of
RIPA Buffer (150 mM sodium chloride, 50 mM Tris, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate) or phosphate buffered saline plus complete pro-
tease inhibitors (PBS) (Roche Applied Science) by
mechanical disruption using a dounce homogenizer.
Total protein content was determined using the DC
protein Assay (Biorad). Samples that were homogenized
in PBS were treated with PNGase F (15 U/μg protein)
(New England Biolabs) for 3 hours shaking at 37°C to
cleave N-linked glycans. The resultant total brain pro-
tein and recombinant protein samples were denatured
in SDS denaturing buffer (Invitrogen) and b-mercap-
toethanol for 10 minutes at 100°C, prior to separation
by SDS-PAGE gel electrophoresis using precast 16% or
4-20% Tris-glycine gels (Invitrogen). Proteins were
transferred to PVDF membrane prior to blocking in 5%
milk PBS for 1 hour before incubating over-night with
primary antibody at 4°C. Membranes were then incu-
bated with an anti-rabbit secondary antibody (Sigma-
Aldrich) conjugated to alkaline phosphatase prior to
development with CDP-Star (Roche Applied Sciences)
and exposure to X-ray film. See-Blue plus 2 (Invitrogen)
was used as a molecular weight marker.
Immunohistochemistry
Whole Tc1 and non-transchromosomic control mouse
brain was fixed by immersion in 10% buffered formal
saline (Pioneer Research Chemicals). Following further
washing for 24 hr in 10% buffered formal saline, tissue
samples were processed and embedded in paraffin wax.
Sections were cut at a thickness of 4 μm. Alternatively
brains were protected in Tissue-Tek (Siemens Health-
care Diagnostics) and frozen by immersion in isopen-
tane chilled with liquid nitrogen. Frozen sections were
cut at a thickness of 10 μm on a cryostat and air dried
prior to staining. Paraffin-embedded sections were pre-
treated by protease digestion. Staining with the rabbit
polyclonal antibodies was undertaken using a Ventana
automated immunohistochemical staining machine
(Ventana Medical Systems, Tuscon, AZ, USA) as
described previously [16]. A biotinylated-anti-rabbit IgG
secondary antibody (iView SA-HRP, Ventana Medical
Systems) was used before development with 3′3 diami-
nobenzidine tetrachloride as the chromogen (iView
DAB, Ventana Medical Systems). Haematoxylin was
used as the counter-stain.
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